IMRT vs Proton Therapy in Esophageal Cancer

Video

This video reviews the advantages and disadvantages of IMRT and proton therapy for the treatment of esophageal cancer.

The current standard for treating patients with esophageal cancer is 3D radiation, but newer technologies such as intensity-modulated radiation therapy (IMRT) and proton therapy have shown the ability to reduce toxicity by limiting radiation to the surrounding tissue.

In this video, Steven H. Lin, MD, PhD, of the University of Texas MD Anderson Cancer Center, reviews IMRT and proton therapy, discussing some of the advantages and disadvantages.

Recent Videos
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Related Content
Findings from the HERIZON-BTC-01 trial support HER2 as a valid therapeutic target in biliary tract cancer.

Zanidatamab Shows Meaningful Benefit in HER2+ Biliary Tract Cancer

Russ Conroy
December 1st 2025
Article

Findings from the HERIZON-BTC-01 trial support HER2 as a valid therapeutic target in biliary tract cancer.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?

How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?

Ariana Pelosci
November 18th 2025
Article

Results from the NAPOLI 3 trial found NALIRIFOX is a viable option for first-line treatment of metastatic pancreatic adenocarcinoma.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Receiving treatment at an academic center may improve the probability of receiving subsequent curative care among those with hepatocellular carcinoma.

Post-IO Curative Treatment Conversion May Prolong Survival in Liver Cancer

Russ Conroy
November 14th 2025
Article

Receiving treatment at an academic center may improve the probability of receiving subsequent curative care among those with hepatocellular carcinoma.

Results from the phase 3 COMPETE trial demonstrated that 177Lu-edotreotide improved PFS and ORR compared with everolimus in patients with GEP-NETs.

FDA Accepts New Drug Application for 177Lu-Edotreotide in GEP-NETs

Tim Cortese
November 14th 2025
Article

Results from the phase 3 COMPETE trial demonstrated that 177Lu-edotreotide improved PFS and ORR compared with everolimus in patients with GEP-NETs.